Last reviewed · How we verify
Metformin, Ethinylestradiol 30µg-Drospirenone
At a glance
| Generic name | Metformin, Ethinylestradiol 30µg-Drospirenone |
|---|---|
| Also known as | metformin, yasmin |
| Sponsor | Iuliu Hatieganu University of Medicine and Pharmacy |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Metformin+ Drospirenone/ethinylestradiol30µg and Flow-mediated Dilation in Polycystic Ovary Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: